MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
Status:
Recruiting
Trial end date:
2023-08-30
Target enrollment:
Participant gender:
Summary
This is a prospective, multicentre randomised, phase II clinical trial, with randomisation
2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.
Phase:
Phase 2
Details
Lead Sponsor:
Australasian Gastro-Intestinal Trials Group
Collaborators:
Australian Government Department of Health and Ageing Trans Tasman Radiation Oncology Group Trans-Tasman Radiation Oncology Group (TROG)